Microgravity-Enabled Biomanufacturing for High-Value Pharmaceutical Ingredients and Space Biotechnology Commercialization

This study explores the development of high-value bio-based raw materials and pharmaceutical ingredients under microgravity conditions in low Earth orbit (LEO), particularly on the International Space Station (ISS). Microgravity reduces sedimentation and convection, enabling more uniform protein and antibody crystallization, which supports API polymorph discovery and improved drug formulation stability. Microgravity also promotes three-dimensional cell aggregation and tissue formation, creating new opportunities for stem cell expansion, organoid production, and bioprinting-based tissue manufacturing. Recent commercial activities by companies such as Varda Space, Merck, Space Tango, and Redwire indicate that space-based biomanufacturing is moving from research toward early-stage commercialization. This research provides a data-driven overview of key technologies, leading industrial players, and market outlook, highlighting the potential growth of space biotechnology from high-value pharmaceutical production to broader biomanufacturing applications in future commercial LEO platforms.